Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Evergreen Therapeutics
Company Location: Eastern America
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Cognitive Dysfunction|Lupus Erythematosus, Systemic|Lupus Vasculitis|Systemic Vasculitis|Vasculitis, Central Nervous System
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07281105 |
Efficacy and Safety Study | P2 |
Completed |
Lupus Vasculitis|Cognitive Dysfunction|Lupus Erythematosus, Systemic|Systemic Vasculitis|Vasculitis, Central Nervous System |
2025-08-12 |
2025-12-16 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|
